Blood-Brain Barrier Disruption Chemotherapy

John M. McGregor; Susan D. Bell; Nancy Doolittle; Tulio P. Murillo; Edward A. Neuwelt

doi:10.1016/B978-0-12-812100-9.00010-3

Blood-Brain Barrier Disruption Chemotherapy

John M. McGregor, Susan D. Bell, Nancy Doolittle, Tulio P. Murillo, Edward A. Neuwelt

Neurology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

3 Scopus citations

Abstract

The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving the neurocognitive function and minimizing systemic toxicity. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as the primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors such as anaplastic oligodendroglioma and central nervous system metastases. Multicenter clinical trials using BBBD are in progress at centers participating in the blood-brain barrier (BBB) Consortium. Current and future clinical studies include delivery of mAbs across the BBB and novel imaging agents to monitor therapeutics.

Original language	English (US)
Title of host publication	Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy
Subtitle of host publication	Second Edition
Publisher	Elsevier Inc.
Pages	145-153
Number of pages	9
ISBN (Print)	9780128121009
DOIs	https://doi.org/10.1016/B978-0-12-812100-9.00010-3
State	Published - Apr 24 2018

Keywords

Blood-brain barrier disruption
Brain tumors
Chemotherapy
Primary CNS lymphoma

ASJC Scopus subject areas

Medicine(all)
Neuroscience(all)

Access to Document

10.1016/B978-0-12-812100-9.00010-3

Cite this

@inbook{cbc4c22a73f24d968d08377a9efdc7fb,

title = "Blood-Brain Barrier Disruption Chemotherapy",

abstract = "The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving the neurocognitive function and minimizing systemic toxicity. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as the primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors such as anaplastic oligodendroglioma and central nervous system metastases. Multicenter clinical trials using BBBD are in progress at centers participating in the blood-brain barrier (BBB) Consortium. Current and future clinical studies include delivery of mAbs across the BBB and novel imaging agents to monitor therapeutics.",

keywords = "Blood-brain barrier disruption, Brain tumors, Chemotherapy, Primary CNS lymphoma",

author = "McGregor, {John M.} and Bell, {Susan D.} and Nancy Doolittle and Murillo, {Tulio P.} and Neuwelt, {Edward A.}",

year = "2018",

month = apr,

day = "24",

doi = "10.1016/B978-0-12-812100-9.00010-3",

language = "English (US)",

isbn = "9780128121009",

pages = "145--153",

booktitle = "Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Blood-Brain Barrier Disruption Chemotherapy

AU - McGregor, John M.

AU - Bell, Susan D.

AU - Doolittle, Nancy

AU - Murillo, Tulio P.

AU - Neuwelt, Edward A.

PY - 2018/4/24

Y1 - 2018/4/24

N2 - The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving the neurocognitive function and minimizing systemic toxicity. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as the primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors such as anaplastic oligodendroglioma and central nervous system metastases. Multicenter clinical trials using BBBD are in progress at centers participating in the blood-brain barrier (BBB) Consortium. Current and future clinical studies include delivery of mAbs across the BBB and novel imaging agents to monitor therapeutics.

AB - The goal of chemotherapy administered in conjunction with blood-brain barrier disruption (BBBD) is maximizing drug delivery to the brain, while preserving the neurocognitive function and minimizing systemic toxicity. In the clinic, BBBD has shown promising results in chemosensitive brain tumors such as the primary central nervous system lymphoma (PCNSL) and offers a new strategy for global delivery of chemotherapy to tumors such as anaplastic oligodendroglioma and central nervous system metastases. Multicenter clinical trials using BBBD are in progress at centers participating in the blood-brain barrier (BBB) Consortium. Current and future clinical studies include delivery of mAbs across the BBB and novel imaging agents to monitor therapeutics.

KW - Blood-brain barrier disruption

KW - Brain tumors

KW - Chemotherapy

KW - Primary CNS lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85054625906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054625906&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-812100-9.00010-3

DO - 10.1016/B978-0-12-812100-9.00010-3

M3 - Chapter

AN - SCOPUS:85054625906

SN - 9780128121009

SP - 145

EP - 153

BT - Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy

PB - Elsevier Inc.

ER -

Blood-Brain Barrier Disruption Chemotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this